Screening Mongolians in France for hepatitis B, C and delta
Screens the Mongolian community in France for hepatitis B, C and delta virus infections.
Plain-language title generated from the registry record
Registry title: Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
Key facts
- Where
- Annecy, Bordeaux, Clermont-Ferrand, Créteil, Grenoble, Lille, Lyon, Rennes, Rouen, Strasbourg, and Tours, FranceSee the 11 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for Mongolian people living in France, aged over 15, to be screened for hepatitis B, C and delta.
- Age
- Over 15 years (minimum age 15 Years)
- Sex
- All sexes can join.
- Earlier treatment
- People already followed for viral hepatitis, treated or not treated, cannot join.
Main reasons for not taking part
- Already followed for viral hepatitis, treated or not treated
- Deprived of liberty by a judicial or administrative decision
- Adults under a legal protection measure (guardianship, curators)
- Taking part in other interventional research (except routine care research and some category 2 research)
Read by machine on 12 November 2026.
Where in France
- Centre Hospitalier Annecy GenevoisAnnecy, FranceContact: Frederic HELUWAERT, DrNo longer taking part
- Centre Expert Hépatites Virales Aquitaine, CHU de BordeauxBordeaux, FranceContact: Juliette Foucher, DrNo longer taking part
- CHU de Clermont-FerrandClermont-Ferrand, FranceContact: Armand ABERGEL, PrNo longer taking part
- Hôpital Henri Mondor - Assistante Publique Hopitaux de Paris (APHP)Créteil, FranceContact: Vincent LEROY, PrNo longer taking part
- CHU Grenoble AlpesGrenoble, FranceContact: Marie Noelle Hilleret, DrNo longer taking part
- CHRU LilleLille, FranceContact: Philippe MATHURIN, PrNo longer taking part
- Service d'Hépatologie, Institut d'hépatologie de Lyon, Hôpital Croix-Rousse, Hospices Civils de LyonLyon, FranceContact: Mahé RAFFINNo longer taking part
- CHRU Rennes PontchaillouRennes, FranceContact: Caroline Jezequel, DrNo longer taking part
- CHU de RouenRouen, FranceContact: Ghassan Riachi, DrNo longer taking part
- Hopitaux Universitaires de StrasbourgStrasbourg, FranceContact: Antonio SAVIANO, DrNo longer taking part
- CHRU BretonneauTours, FranceContact: Louis d'Alteroche, DrNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT07038863
- Record updated
- 26 June 2025
- Original description
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%, and hepatitis Delta (HDV) at 40-60% in HBV-infected patients. Viral hepatitis are essentially asymptomatic and therefore require systematic screening for diagnosis. Once a diagnosis of chronic viral infection has been established, specific therapies are available to reduce the morbidity and mortality of these patients. A study carried out in California in the Mongolian community found an HBV prevalence of 9.7% and positive HDV serology in 41% of these patients.Read full original descriptionShow less
Community Screening for Hepatitis B, C and Delta in the Mongolian Population Living in France
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%, and hepatitis Delta (HDV) at 40-60% in HBV-infected patients. Viral hepatitis are essentially asymptomatic and therefore require systematic screening for diagnosis. Once a diagnosis of chronic viral infection has been established, specific therapies are available to reduce the morbidity and mortality of these patients. A study carried out in California in the Mongolian community found an HBV prevalence of 9.7% and positive HDV serology in 41% of these patients.
There is a large Mongolian community in France, estimated at between 5,000 and 6,000 patients. Although the majority of these patients are covered by French social security; however, access to care and screening for viral hepatitis often remain difficult and insufficient for migrant or vulnerable populations in France The aim of this study is to screen the Mongolian community in France for viral hepatitis, and then initiate a program of care and treatment.
Inclusion: Mongolian people; Over 15 years of age; Living in France; Majors agree to participate or minors whose parental guardians agree to their child's participation in the study.
Exclusion: People already followed for viral hepatitis, treated or not treated; Persons deprived of their liberty by a judicial or administrative decision; Adults subject to a legal protection measure (guardianship, curators); People participate in any interventional research except routine care research (old regulation) and category 2 research that does not interfere with the primary endpoint analysis.